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he Conundrum of
unctional Mitral Regurgitation
n Chronic Heart Failure*
aurice Enriquez-Sarano, MD, FACC,†
idier F. Loulmet, MD,‡
aniel Burkhoff, MD, PHD§
ochester, Minnesota; and New York, New York
eart failure begets mitral regurgitation (MR); MR begets
eart failure. This incestuous and insidious relationship has
ong been known to contribute to the positive feedback loop
hat underlies progressive, pathologic ventricular remodel-
ng in chronic heart failure (CHF). Yet, despite decades of
nvestigation and thought, important questions have gone
nanswered, many with direct relevance to the care of CHF
atients with MR. Fundamentally, these questions revolve
round understanding how much MR contributes to symp-
oms and disease progression, whether to intervene and, if
o, when to intervene surgically to eliminate MR. With lack
f randomized clinical trials proving benefit, along with
ssociated risks, surgical correction of MR is not performed
See page 476
requently as a standalone procedure in patients whose
rimary problem is a dilated failing heart. However, several
ifferent approaches for percutaneous mitral repair are
urrently in development and will soon provide less invasive
lternatives that could facilitate such questions being ad-
ressed. Therefore it is relevant and important to refocus
ttention on understanding the role of MR in the patho-
enesis and progression of CHF. In this regard, the study
eported by Beeri et al. (1) in this issue of the Journal
rovides an important contribution.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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thies, ventricular remodeling (dilation and deformation)
ccurs and can be associated with mitral annular distortion
nd/or dilation. Papillary muscles might be infarcted or can be
ysfunctional during periods of ischemia. Importantly, recent
tudies have revealed that apical and posterior displacement of
ne or both papillary muscles due to left ventricular (LV)
ysfunction and remodeling are critical in initiating MR (2–4).
uch displacement causes traction on the inextensible chordae
endinae, particularly the strut chords attached to the body of
oth mitral leaflets. This pulls the leaflets into the LV,
esulting in “tenting” of the valve over the plane of the annulus
nd a reduced area of leaflet coaptation. In turn, the reduced
oaptation leads to formation of a regurgitant orifice. Such MR
ccurring in the setting of LV dilation with structurally normal
eaflets is referred to as functional mitral regurgitation (FMR).
his is distinguished from organic mitral regurgitation, which
ccurs in the setting of primary valve pathology, as in rheu-
atic heart disease.
By the time most patients present with symptoms of heart
ailure, ventricular dilation and MR are typically both
resent. Although the degree of FMR can be reduced in
ome cases by optimizing medical therapies (afterload re-
uction and treatment of fluid overload), many patients
ersist with significant FMR. In the clinical setting, how-
ver, it is usually difficult if not impossible to tease out the
elative contributions of the primary pump dysfunction and
MR to LV remodeling and patient symptoms. Conse-
uently it is not known for a given patient whether fixing
MR will improve symptoms or play any role in reversing
entricular dilation and pump dysfunction.
Clinical studies of the role of FMR provide a somewhat
onfusing message. On the one hand, recent data suggest
hat even moderate FMR (30 ml/beat or effective regur-
itant orifice 20 mm2) has serious clinical consequences
5,6). Patients with FMR incur higher mortality (approxi-
ately twice) and have a greater risk of developing CHF
approximately 4 times) than those without. On the other
and, several prior observational and retrospective studies
uggested that treating ischemic FMR did not lead to
everse remodeling (7), did not provide superior survival
ompared with bypass alone (8,9), and treating cardiomy-
pathy with FMR by valve repair did not seem to provide
etter survival than medical treatment (10). Therefore, some
uthors already consider surgery of FMR as a failed inno-
ation (11). However, these observational results do not
nswer the question of whether FMR influences outcome in
atients with LV dysfunction, particularly because mitral
urgery has had limitations related to recurrence of FMR
ue to ongoing LV remodeling with reappearance of valve
enting after annuloplasty (12,13). The uncertainty regard-
ng FMR is further complicated by the fact that patients
ith FMR also have, in general, worse LV function,
emodeling, and clinical presentation (2,5). Even after
atching patients with and without FMR for ejection
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Editorial Comment January 29, 2008:487–9raction, one might wonder whether lower LV intrinsic
unction (undetected by standard methods) is not the main
river for excess risk (5). Thus, controlled studies are needed
n which the only difference between cases and control
ubjects is the treatment of FMR.
Such was the approach employed by Beeri et al. (1), who
onducted a remarkable experimental study that eliminates
ome of the outstanding uncertainties of clinical studies.
echniques for inducing ventricular dilation and heart
ailure by myocardial infarction are well established in many
nimal species. However, these models don’t always develop
R, even when special attention is given to try to infarct
he papillary muscles and overlying apical and lateral walls
14). Furthermore, when it does occur, the degree of FMR
s difficult to control. Rankin et al. (15) previously described
n animal model of left ventricle-to-left atrial regurgitation
LVAR) as a surrogate for a model of FMR. The model was
reated by surgically placing an extracardiac artificial con-
uit between the LV and the left atrium in otherwise
ormal animals. It was shown that, over time, the presence
f LVAR caused progressive ventricular dilation and myo-
ardial dysfunction as signs of CHF developed. Beeri et al.
1) have now adapted this model to assess the additive role
f FMR to the development of LV remodeling after a
yocardial infarction. Key elements of the model are the
onsistently sized and located apical infarct and the rela-
ively consistent, low-volume, 30% regurgitant fraction
reated by the LVAR. Methodologically, these researchers
ot only analyzed the changes of LV volumes during the
xperiment but also gathered complementary evidence of
unctional and biochemical changes that characterize ongo-
ng LV remodeling. It was observed that the animals with
VAR incurred a much larger increase in LV volume and
lso incurred more severe systolic and diastolic LV alter-
tions, reduced calcium cycling proteins, activation of pro-
ypertrophic signaling pathways, cellular elongation, and
ctivation of metalloproteinases and their inhibitors in the
yocardium remote from the myocardial infarction. Thus,
ven a moderate-volume regurgitant fraction, similar to that
ypically seen clinically with FMR, is not a bystander from
he point of view of progressive LV remodeling but is
irectly linked to excess LV remodeling and functional and
iochemical markers thereof. Thereby, the present study
stablishes a firm link between FMR and excess LV
emodeling, a well-established precursor of clinical events
16).
Certain limitations of the study should be acknowledged.
irst, the size of the myocardial infarctions seems to be
elatively small and by itself leads to only modest dilation. It
s not certain that the additive effect of MR in the setting of
larger infarct will equal that observed in the present study.
econd, it would have been ideal to have included animals
eceiving only the LVAR shunt, so as to evaluate the final
ontribution of the original infarct to the remodeling. It is
onceivable that the effects of the LVAR are so overwhelm-
ng that the initial infarct is actually inconsequential as itelates to the final amount of remodeling observed. Finally,
nd most importantly, it would have been most significant
o have investigated the impact over time of eliminating the
VAR once the animals reached the final stable heart
ailure state. This would have answered the question, at least
or this model, of whether elimination of MR in a dilated
ailing heart can have a beneficial effect on remodeling, LV
unction, and clinical status.
There are several important issues that need to be
ddressed in order to bring us closer to resolving the
onundrum of FMR in the setting of CHF. Prospective
linical studies evaluating the impact of FMR and MR
epair on outcomes are central to advancing understanding.
evelopment of less invasive percutaneous therapies for
reating FMR (17) might provide the means of addressing
uch questions without putting patients through the risks of
urgery. Multiple designs are explored through coronary
inus, annular, or ventricular approaches, which are prom-
sing. Continued investigation through careful preclinical
xperimental work can help fill gaps in understanding that
annot be filled through clinical studies alone. In this
egard, the comprehensive experimental study by Beeri et al.
1) in the present issue of the Journal is an important step in
ursuing this important therapeutic pathway for patients
ith LV dysfunction and CHF who remain at high risk.
eprint requests and correspondence: Dr. Daniel Burkhoff, Divi-
ion of Cardiology, Columbia University, 177 Fort Washington
venue, New York, New York 10032. E-mail: db59@columbia.edu.
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